IL1B and lung carcinoma: Recently, clinical trials targeting IL-1β in patients with atherosclerosis using the monoclonal antibody canakinumab (anti-IL-1β) have shown a direct correlation with decreased incidence of lung cancer, decreased mortality, and better prognosis when compared to patients treated with placebo (55).